T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs
A Phase III Open-Label, Randomized, Active-Controlled Study Assessing the Efficacy and Safety of T-20 (HIV-1 Fusion Inhibitor) in Combination With an Optimized Background Regimen, Versus Optimized Background Regimen Alone, in Patients With Prior Experience and/or Prior Documented Resistance to Each of the Three Classes of Approved Antiretrovirals (Nucleoside Reverse Transcriptase, Non-Nucleoside Reverse Transcriptase and Protease Inhibitors)
Sponsor: Hoffmann-La Roche
Listed as NCT00021554, this PHASE3 trial focuses on HIV Infections and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 6 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
- Trimeris
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands, Antwerp, Belgium, Barcelona, Spain, Basel, Switzerland, Bonn, Germany, Brighton, United Kingdom, Brussels, Belgium, CX Utrecht, Netherlands, Carlton, Australia, Darlinghurst, Australia and 21 more location s